PEPPER

Study added: 02 Apr 2018

Contact

Eric McVey

434-243-5382

edm9u@virginia.edu

Males and females 21 years of age or older
Undergoing elective primary or revision hip or knee replacement
Patient has necessary mental capacity to participate and is able to comply with study protocol requirements
Patient is willing and able to give consent and participate
Patient is willing and able to be randomized

No patient undergoing total hip or knee replacement who has been enrolled in this study for a prior hip or knee replacement can be enrolled for a second hip or knee replacement in this study.
No patient that is currently actively enrolled in another clinical trial may be enrolled in this study.
Women who are pregnant or breastfeeding, as well as those of reproductive potential unless there is a negative urine pregnancy test.
Patients on chronic (longer than the prior 6 months) anticoagulation other than with antiplatelet medications
Documented gastrointestinal, cerebral, or other hemorrhage within 3 months of the operation
A prior episode of hypersensitivity or adverse reaction to heparin
A known diagnosis of defective hemostasis
Within one month of an operative procedure involving the eye, ear, or central nervous system
Severe uncontrolled hypertension with systolic BP > 220mmHg and diastolic BP > 120mmHg
An absolute body weight of less than 41 kilograms (90.4 lbs) on day of enrollment
Vulnerable patient populations including prisoners and institutionalized individuals

Baseline / pre-op. HOOS or KOOS, PROMIS-10, OSWESTRY, Charlson Comorbidity
Randomized. Maximum 1 week before surgery and Minimum 1 day before surgery.
Surgery. Begin DVT prophylaxis before surgery for Aspirin or Warfarin or 24 hours after surgery for Rivaroxaban
3 weeks post op – phone call from GSR, LLC
3 months post op- phone call from GSR, LLC
6 months post op – phone call from GSR, LLC

There is no payment for participation

Contact Sarah Spangler (cc Eric McVey) with patient name, MRN, DOS, study visit